Thoughts on Gene Editing From the Science Community – The Atlantic

Our next group of correspondents stood out due to their vocations: In one way or another, their chosen careers brought them into the subculture of scientific thinking. These readers tended to be more favorably disposed to gene editing than others.

Take this reader, a semi-retired school psychologist and a lover of science whose daughter plans to become a clinical geneticist:

I agree with the premise of your article [that prophylactic gene editing could soon be mandatory] and am not frightened by it at all. Scientific advances have not, cannot, and should not be stopped. Since the first civilizations science has been dragging religion and society reluctantly along into a more technologically advanced future. What we gain from this seems always to be more than what we have lost.

A medical student who hopes one day to do gene editing was likewise eager for a future where it is used to cure diseaseand even to direct the way that humans evolve:

Modern medicine, in its current form, is basically the answer to the question: What is the best way to treat diseases whose cures cannot and will not ever be found? Treating someone with cystic fibrosis, for instance, is an admirable thing to do, but its also an exercise in futility: That patient will undoubtedly die prematurely. Anything besides excising the mutant gene and replacing it with a normal copy is treading water and delaying the inevitable (though, obviously, the patients must still be treated).

In modern societies, infectious diseases and trauma are more or less under control (relative to developing countries and bygone eras). Curing genetic diseases (cancer loosely being included in this category) are currently a dead end. So, logically, addressing this head-on is the only next step.

I view gene therapy and editing as the way of the future, not only of medicine but also of humanity in general. It will start as the means for cures of currently incurable diseases. Eventually, it will be a means by which we can continue to evolve ourselves as a species. If 3.5 billion years of evolution churned our species out through the natural selection of random mutations, how much better can we do with logic and molecular precision? In my opinion, anything that can widely (and, potentially, permanently) change mankind and society for the better should be done.

I wish I shared the correspondents confidence that logic and molecular precision will serve humanity better in this realm than the decentralized systems of dating and mating have done so far. Reflecting on the decisions that literally every bygone generation might have made if able to edit genes, I fear that our choices will prove as imprudent in hindsightand thats not even accounting for unintended consequences.

The next reader is working to earn his Masters degree in Biochemistry:

It is not unreasonable to imagine that in the near future gene editing will be a safe and effective means of preventing genetic diseases. It is also not unreasonable to imagine that in the case of many diseases, such as sickle-cell anemia or cystic fibrosis, which are caused by small mutations in a single gene coding for a functionally important protein, gene editing would be likely to prevent the disease without affecting the child in any other way. For these diseases, once it is demonstrated that gene editing works the way that it is supposed to, I think parents should be punished for failing to employ gene editing. I think that if it had been demonstrated that gene editing was safe, effective, and selective, refusal to use this technique to prevent disease would essentially amount to fear and mistrust of the scientific and medical communities. I really dont think thats a valid reason to allow another person to be afflicted by a preventable disease.

However, I draw a distinction here between expecting parents to make edits that will definitely prevent a debilitating disease, and expecting edits that reduce the risk of a disease that the child may or may not have ended up getting. I certainly wouldnt be opposed to parents editing genes to reduce the chance of cancer, but I wouldnt really expect it. There are a number of behaviors that we know reduce cancer risk which we dont really expect parents to push on their kids. For example, parents could probably reduce cancer risk in their children by some small fraction by giving them grape juice every day or something like that. I dont really expect parents to do that. If you cant blame parents for not giving their kids grape juice you really cant blame them for not editing the kids genome.

At the same time, he adds, we can really only justify using gene editing for medical purposes:

We are a long way from understanding our biology well enough to be able to make genome modifications to enhance intelligence or beauty or athleticism without risking horrible unforeseen side effects. But even if we did have the ability to do that, I still dont think it would be justified because I dont think we can tie these traits to an increased sense of happiness or fulfillment.

I am short and scrawny, and Im perfectly happy with that. I know plenty of people who are perfectly content with being as dumb as rocks. I know plenty of smart people who are miserable. So, Ill grant that I am basing my opinion here on a biased personal experience, but I really dont think that we can say that it really is in the best interests of the child to alter superficial traits.

When discussing a childs future, people often talk as if the parents preference is the most important thing. But parents dont own their children. Parents are stewards of their children. I think that making designer babies would be an example of parents making self-serving decisions, rather than making decisions in the best interests of the child. I dont think that is justifiable.

The next correspondent is a biochemistry grad student who works in a research group that specializes in genome-editing technology, and cautions against its near-term limits:

If gene therapy with Cas9 were at some future time as cheap, easy, and safe as an antibiotic treatment, then yes, I would support punishments for parents who forewent a cure for their children. In some cases, a genetic disorder is very similar to other macro-level disorders, e.g. genes can be broken in the same sense that a wrist is broken. While wrists can come in many healthy shapes and sizes and colors, broken in two is not one of them; likewise, while genetic diversity is important and natural and cant always be cleanly mapped to disease, some genetic mutations are incontrovertibly damaging and lead to illness and suffering. Refusing a simple medical treatment for a disorder with a clear singular genetic root cause (of which there are fewer than one might think) would be as unethical as refusing to set a broken wrist.

But I dont think gene therapy will be as cheap, easy, or safe as antibiotics in our lifetimerather, my opinion is that gene therapy will be expensive, invasive, and risky (at least relative to an antibiotic pill) for the foreseeable future. I dont expect gene therapy to become routine in the same way that oral therapies are, and so choosing not to subject your child to gene editing cannot be chalked up to negligence. (A contemporary example: Sovaldi is a drug that essentially cures Hepatitis C, but it costs $200,000 and there are other treatmentscould you imagine a parent being prosecuted for refusing to pay for Sovaldi?)

Why am I so down on gene therapy?

First of all, regarding cost, the clamor surrounding the Cas9 patent dispute should give you an idea of how profitable the players in this field expect gene therapy to be. Gene therapy will always be more expensive than an oral antibiotic because the treatment requires many more steps (each of which is far costlier), is much lower throughput, and will require specialized care and oversight. For similar reasons, it will not be nearly as convenient for patients as filling a prescription. And as Ive written elsewhere, our current early-generation gene-therapy tools and limited understanding of the link between genetics and disease means that gene therapy carries unprecedented safety risks. (For example, no currently approved therapy could cause permanent heritable genetic changes.)

These risks shouldnt disqualify gene therapy as a possible future treatment, but they could certainly give the most informed and adventurous patient pause. In short, I believe technical limitations and cost and safety concerns will delay the debate over mandatory gene editing for decades at least. More pressing to discuss are the multitude of other ways that gene editing and GMOs affect modern life and medicine.

Go here to read the rest:
Thoughts on Gene Editing From the Science Community - The Atlantic

University of Rochester School of Medicine and Dentistry Collaborate with Admera Health in a Clinical Study … – GlobeNewswire (press release)

May 09, 2017 09:13 ET | Source: Admera Health, LLC

SOUTH PLAINFIELD, N.J. and ROCHESTER, N.Y., May 09, 2017 (GLOBE NEWSWIRE) -- Today, the University of Rochester School of Medicine and Dentistry and Admera Health announced that enrollment had commenced in a randomized clinical study evaluating the use of pharmacogenomics to guide pain management decisions related to acute dental surgery. Specifically, the study is seeking to determine if a preoperative chair-side pharmacogenomic algorithm can significantly enhance the efficacy of surgical pain management and to characterize the association between gene-drug interactions and clinical outcomes.

Admera Health, a molecular diagnostic company, will extract and sequence DNA samples provided by the University of Rochester. Sequencing will utilize Admeras PGxOne Plus test, a 50 gene Next Generation Sequencing panel that interrogates nearly 200 different variants and provides recommendations for over 220 drugs based on an individuals unique genetic makeup.

It is well understood in the medical community that most acute surgical pain methods have shown inconsistent effects on pain relief and rely excessively on opioid use, which has associated dependency issues, as stated by Admera CEO and President Guanghui Hu. With the implementation of our PGxOne Plus test, we are confident that this study will demonstrate improved patient outcomes, similar to the way pharmacogenomics has been clinically validated in other therapeutic areas such as cardiovascular health, oncology, and psychiatric care. That is why we are excited to be working with the University of Rochester for this study.

According to the CDC, opioid-involved deaths continue to increase and have reached epidemic status. In March, a United States Senate committee opened a probe into the practices of the top manufacturers of opioid drugs.

About Admera Health

Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.

Related Articles

South Plainfield, New Jersey, UNITED STATES

http://www.admerahealth.com/

Admera Health, LLC Logo

LOGO URL | Copy the link below

Formats available:

More:
University of Rochester School of Medicine and Dentistry Collaborate with Admera Health in a Clinical Study ... - GlobeNewswire (press release)

Professor Emeritus Wins Prestigious ACS Award in Theoretical Chemistry – University of Arkansas Newswire

Photo Submitted

Peter Pulay

Peter Pulay, professor emeritus of the Department of Chemistry and Biochemistry in the J. William Fulbright College of Arts and Sciences, was recently named the recipient of the 2017 American Chemical Society Award in Theoretical Chemistry.

The prestigious award is given to one recipient a year, in recognition of their innovative research in theoretical chemistry, that either advances theoretical methodology or contributes to new discoveries about chemical systems.

According to the American Chemical Society, emphasis in the selection process is on work characterized by depth, originality, and scientific significance.

"I can think of no better recipient than Peter," said Wesley Stites, chair of the Department of Chemistry and Biochemistry. "He is well-deserving of this honor, and is in great company past recipients of this award include multiple Nobel Prize winners as well."

Pulay joined the university in 1982 and retired in 2016. He is among the top 300 most highly cited living chemists in the world, with one of his publications cited 3,905 times and five others each cited more than 1,000 times. His total body of work has been cited more than 27,000 times and he holds the title of "Citation Classic" by the Institution of Scientific Information.

"We are incredibly proud to have him represent our university, college and department," Stites said.

Prior to his retirement, Pulay was a distinguished professor and held the Roger Bost Professorship of Chemistry and Biochemistry.

Pulay is considered by his peers to be one of the top five researchers in his field. He has received numerous honors including the Medal of the International Academy of Quantum Molecular Sciences, the Alexander von Humboldt Senior Scientist Award and the Schredinger Medal of the World Association of Theoretical and Computational Chemists.

Early in his career he developed techniques for determining the shape and size of molecules that would permanently change the way scientists study matter.

His approach is now widely used by theoretical chemists around the world, and the Royal Swedish Academy credited this work to being crucial in a 1998 Nobel Prize.

Editor-selected comments will be published below. No abusive material, personal attacks, profanity, spam or material of a similar nature will be considered for publication.

Read more from the original source:
Professor Emeritus Wins Prestigious ACS Award in Theoretical Chemistry - University of Arkansas Newswire

New plutonium discovery lights way for chemistry professor’s work to clean up nuclear waste – Science Daily


Science Daily
New plutonium discovery lights way for chemistry professor's work to clean up nuclear waste
Science Daily
The work was published today in Nature Chemistry. Albrecht-Schmitt and a team of researchers have been studying plutonium -- Pu on the Periodic Table of Elements -- for almost two decades to understand how it behaves chemically, and how it differs from ...
Plutonium research to aid nuclear cleanup techniquesUPI.com

all 3 news articles »

Go here to read the rest:
New plutonium discovery lights way for chemistry professor's work to clean up nuclear waste - Science Daily

‘Heroes of Chemistry’ improve people’s lives through the transforming power of chemistry – Canada Free Press

WASHINGTON Scientists who developed products that have led to significant advancements in human health, technology, the food supply, and the environment, will be inducted into a scientific Hall of Fame later this summer, becoming the newest Heroes of Chemistry, an honor bestowed by the American Chemical Society (ACS), the worlds largest scientific society.

Through the 2017 ACS Heroes of Chemistry program, we are honoring scientists from Bristol-Myers Squibb, Corning, Dow Chemical, DuPont Crop Protection, Genentech, and Merck whose risk-taking and drive to innovate have contributed to the advancement of the human condition, says Allison Campbell, ACS president. Their creative spirit, commitment to excellence, and technical talent are tangible evidence of the ACS Vision: Improving peoples lives through the transforming power of chemistry.

The Heroes of Chemistry program recognizes scientists whose innovative work in chemistry and chemical engineering led to commercial products that benefit the world. The teams will be recognized in a ceremony on Sunday, Aug. 20, during the Societys 254th National Meeting & Exposition in Washington, D.C.

The following scientific teams will be honored:

The American Chemical Society is a not-for-profit organization chartered by the U.S. Congress. ACS is the worlds largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

Go here to read the rest:
'Heroes of Chemistry' improve people's lives through the transforming power of chemistry - Canada Free Press

Prizes and awards 2017 – Royal Society of Chemistry

Professor Thomas Carell Alexander Todd-Hans Krebs Lectureship in Chemical Sciences 2017

Professor Manfred Bochmann Applied Inorganic Chemistry Award 2017

Professor Michael Greaney Bader Award 2017

Dr David Fairen Jimenez Barrer Award 2017

Professor Thomas Ward Bioinorganic Chemistry Award 2017

Professor Kieron Burke Bourke Award 2017

Professor Julia Weinstein Chemical Dynamics Award 2017

Dr Alexander Hinz Dalton Emerging Researcher Award 2017

Professor Ning Yan ESED Early Career Award 2017

Dr Andrew Lawrence Hickinbottom Award 2017

Professor Neil Garg Higher Education Teaching Award 2017

UCL Chemistry Lab Technician Team Higher Education Technical Excellence Award 2017

Professor Syuzanna Harutyunyan Homogeneous Catalysis Award 2017

Professor Robert Morris Inorganic Mechanisms Award 2017

Professor R. Scott Prosser Jeremy Knowles Award 2017

Professor Stephen Elliott John B Goodenough Award 2017

Dr Nicholle Bell Joseph Black Award 2017

Professor Warren Warren Liversidge Award 2017

Professor Karsten Meyer Ludwig Mond Award 2017

Dr Steven Lee Marlow Award 2017

Professor Phil Baran Merck, Sharp & Dohme Award 2017

Dr Mark Howarth Norman Heatley Award 2017

Professor Nicholas Turner Organic Stereochemistry Award 2017

Professor William Jones Organometallic Chemistry Award 2017

Professor Jin-Quan Yu Pedler Award 2017

Professor Saiful Islam Peter Day Award 2017

Professor Michael Wasielewski Physical Organic Chemistry Award 2017

Membrane Biophysics Platform Rita and John Cornforth Award 2017

Professor Dale Boger Robert Robinson Award 2017

Mr Matthew Wallace Ronald Belcher Award 2017

Professor Gustavo Scuseria S F Boys-A Rahman Award 2017

Dr Kristy Turner Schools Education Award 2017

Professor Aidan McDonald Sir Edward Frankland Fellowship 2017

Professor Antony Cass Sir George Stokes Award 2017

Professor Douglas Tobias Soft Matter & Biophysical Chemistry Award 2017

Professor Richard Van Duyne Spiers Memorial Award 2017

Professor Omar Yaghi Spiers Memorial Award 2017

Professor Xiao Cheng Zeng Surfaces & Interfaces Award 2017

Professor Javier Prez-Ramrez Sustainable Energy Award 2017

Professor Varinder Aggarwal Synthetic Organic Chemistry Award 2017

Professor Christopher Elliott Theophilus Redwood Award 2017

Professor Andrew Smith Toxicology Award 2017

Read the original:
Prizes and awards 2017 - Royal Society of Chemistry

ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain – Barron’s


Barron's
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain
Barron's
Meanwhile the SPDR S&P Biotech ETF (XBI), the SPDR S&P Pharmaceuticals ETF (XPH), and the First Trust NYSE Arca Biotechnology Index (FBT) fell about 2.7% apiece. The AHCA could have both positive and negative impact on pharma and biotech, but ...
Direxion Daily S&P Biotech Bear 3X Shares (LABD): The Quick Guide to LABDInvestorplace.com

all 38 news articles »

See original here:
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain - Barron's

Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review – Los Angeles Business Journal

Puma Biotechnology Inc.s stock took a dive last week after its regulatory executive resigned less than three weeks before a U.S. Food and Drug Administration panel is scheduled to review the public companys breast cancer drug Neratinib.

The Westwood companys share price dipped 14 percent to $31.38 at the close of business May 5 from $36.45 the day before, when the company notified the Securities and Exchange Commission that Robert Charnas, senior vice president of regulatory affairs and project management, would step down for health reasons effective May 15.

The stock was trading at $29.15 when the markets closed Monday.

The company, which has a market cap of $1.07 billion, hired 63-year-old Charnas last year with a base salary of more than $330,000, stock options, and a more than $378,000 signing bonus, according to the employment offer letter filed with the SEC.

An independent panel of experts is scheduled to review Neratinib for safety and efficacy May 24 before making a recommendation for its use to the FDA.

Caroline Anderson is a staff reporter covering retail, restaurants, and hospitality. She can be reached at canderson@labusinessjournal.com.

More here:
Puma Biotechnology Stock Slumps as Regulatory VP Departs Before FDA Review - Los Angeles Business Journal

Puma Biotechnology Inc (PBYI) Plunges 5.54% on May 08 – Equities.com

Market Summary Follow

Puma Biotechnology Inc is a A biopharmaceutical company

PBYI - Market Data & News

PBYI - Stock Valuation Report

Puma Biotechnology Inc (PBYI) had a rough trading day for Monday May 08 as shares tumbled 5.54%, or a loss of $-1.7 per share, to close at $29.00. After opening the day at $30.45, shares of Puma Biotechnology Inc traded as high as $31.20 and as low as $28.50. Volume was 1.11 million shares over 8,212 trades, against an average daily volume of 941,762 shares and a total float of 36.97 million.

As a result of the decline, Puma Biotechnology Inc now has a market cap of $1.07 billion. In the last year, shares of Puma Biotechnology Inc have traded between a range of $73.27 and $19.74, and its 50-day SMA is currently $38.11 and 200-day SMA is $43.37.

For a complete fundamental analysis of Puma Biotechnology Inc, check out Equities.coms Stock Valuation Analysis report for PBYI.

Want to invest with the experts? Subscribe to Equities Premium newsletters today! Visit http://www.equitiespremium.com/ to learn more about Guild Investments Market Commentary and Adam Sarhans Find Leading Stocks today.

Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care.

Puma Biotechnology Inc is based out of Los Angeles, CA and has some 160 employees. Its CEO is Alan H. Auerbach.

Puma Biotechnology Inc is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

To get more information on Puma Biotechnology Inc and to follow the companys latest updates, you can visit the companys profile page here: PBYIs Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.coms Newsdesk. Also, dont forget to sign-up for our daily email newsletter to ensure you dont miss out on any of our best stories.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Read more:
Puma Biotechnology Inc (PBYI) Plunges 5.54% on May 08 - Equities.com

Bioengineering researchers showcase work | Scoop News – Scoop.co.nz (press release)

Tuesday, 9 May 2017, 3:28 pm Press Release: University of Auckland

Bioengineering researchers showcase work at Waikato Mori school

Researchers from the University of Aucklands Bioengineering Institute (ABI) will step outside their laboratories tomorrow and spend a day with 40 Year nine and ten pupils at Ng Taitea School in Hamilton.

They will work hands-on with students demonstrating things like the intricate workings of our noses and eyes and how a baby breathes in vitro.

This is the second year in a row the ABI, in partnership with Medical Technologies Centre of Research Excellence (MedTech CoRE) Outreach, has held an innovation day at Ng Taitea Wharekura.

The Outreach programme aims to build strong relationships with students at high school level and then provide support as they progress to University, says Diana Siew, MedTechCoREs Strategic Relationships Manager, based at ABI.

The MedTech CoRE Outreach has been co-designed with Ng Taitea Wharekura and aims to target the Mori community, particularly lower decile schools giving a little extra support to interested students to help them pursue STEM-related subjects.

Our goal is not necessarily clinically oriented, says Siew. Students moving into tertiary education through our programme will have a chance to be mentored by our researchers adding support during their studies and potentially even achieve postgraduate qualifications.

Last year we ran our pilot innovation day with Ng Taitea Wharekura, this year we have extended the invitation to include the wider high school communities of the region.

Mel Veituna, Head of Learning in the Community at Ng Taitea, says: The students of Ng Taitea Wharekura benefit from the interactions with MedTech CoRE because it opens their eyes to a whole range of career possibilities out there.

These students are passionate about science, and it is inspiring for them to see people working in these types of careers. To hear about it is one thing, but our students are lucky enough to be able to see it with their own eyes.

Five Bioengineering Research Groups will be showcasing their work tomorrow. These include NIHI, the National Institute for Health Innovation, which is developing an app and website aimed at reducing risks of diabetes, obesity and heart disease for Mori and Pasifika Communities.

Research fellow Dr Hari Kumar and his team will use a printed replica of a human nose to show the inside of the nose including sinuses. We shall explain flow resistance and why breathing becomes difficult when the nose is obstructed. We will also use basic geometry and relate to functioning of the nose, says Dr Kumar.

Senior Research Fellow Dr Alys Clark will take students through the life of an unborn child. There is no air in the womb so babies have to get all their oxygen from the mother via the placenta, she says. Well do some experiments to show how this works, and what effects smoking and diet can have on this delicate process.

Members of ABIs Eye Group, Dr Jason Turuwhenua and Dr Peng Guo will demonstrate eye structure with a tangible model. To inspire our students, we will also show some computer technologies used for visual acuity measurement, including some face tracking and eye tracking devices, says Dr Turuwhenua.

http://www.abi.auckland.ac.nz/en.html

Scoop Media

Follow this link:
Bioengineering researchers showcase work | Scoop News - Scoop.co.nz (press release)

Global Biochemistry Analyser Market Driven by the Increase in Lab Automation: Technavio – Business Wire (press release)

LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global biochemistry analyser market is projected to grow to USD 13,340.13 million by 2021, at a CAGR of more than 6% over the forecast period.

This research report titled Global Biochemistry Analyser Market 2017-2021 provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The biochemistry analyser is a commonly used lab equipment, which is used for measuring and diagnosing biological samples such as blood, cerebral fluid, urine, etc. The increase in laboratory automation, combined with the biochemistry analysers ability to run 9,000 to 10,000 tests per day is resulting in its increased adoption.

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Based on the end-users, the report categorizes the global biochemistry analyser market into the following segments:

Hospital and diagnostic laboratories

Hospitals and diagnostic laboratories lead the revenue generation in the biochemistry analyser market, where these products are required for disease diagnosis, treatment, treatment monitoring, disease surveillance, and clinical research, says Krishna Venkataramani, a lead analyst at Technavio for lab equipment research.

Hospitals and diagnostic laboratories use lab equipment such as biochemistry analysers to perform tests on samples of blood, plasma, serum, or urine to determine the concentration of analytes like cholesterol, glucose, and calcium using the biochemistry analyser.

Home care

The biochemistry analyser market by the home care sector is expected to be worth USD 4,331.5 million by 2021. The use of biochemistry analysers to perform various healthcare diagnoses to reduce the length of hospital stays and provide additional medical assistance are quickly driving the growth of the market segment. Home care is considered less expensive, more convenient, and is as effective as care provided by hospitals or trained nursing facilities, which ensures a constant demand for biochemistry analysers from the segment.

Academic and research institutes

The focus of academic and research institutes is to test and analyze innovative and diagnostic solutions like the biochemistry analyser, using data related to patients' diagnoses to help them recommend subsequent treatments, says Krishna.

Various diagnostic solutions are used by academic and research institutes to analyze and understand various biomolecule structures present in biological systems to diagnose diseases so that new drug discoveries can be made for effective therapeutic treatment.

The top vendors highlighted by Technavios research analysts in this report are:

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as theyre published in addition to all 6,000+ existing reports covering segments like agricultural equipment, health and wellness, and outdoor gear. This subscription nets you thousands in savings, while staying connected to Technavios constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

More:
Global Biochemistry Analyser Market Driven by the Increase in Lab Automation: Technavio - Business Wire (press release)

Fat metabolism in live fish: Real-time lipid biochemistry observed … – Science Daily


Science Daily
Fat metabolism in live fish: Real-time lipid biochemistry observed ...
Science Daily
Studying how our bodies metabolize lipids such as fatty acids, triglycerides, and cholesterol can teach us about cardiovascular disease, diabetes, and other ...

and more »

Here is the original post:
Fat metabolism in live fish: Real-time lipid biochemistry observed ... - Science Daily

State Anatomy Board overwhelmed with unclaimed bodies – WBAL Baltimore

BALTIMORE

With the number of overdoses in the state growing, the Office of the Chief Medical Examiner is overwhelmed with cases.

Download the WBAL app

The office recently got the go-ahead to hire more staff to help with autopsies, and another office is also seeing an increase in bodies for a variety of reasons.

After 72 hours, bodies that are not claimed are under the control of the State Anatomy Board.

The State Anatomy Board is housed in the University of Maryland Medical Center. It is where unclaimed bodies end up, and according to its director, since fiscal year 2012, the number of bodies that end up there has gone up significantly.

"The deceased come to us because maybe the families don't have the economic means to make a claim and the deceased didn't have the insurance, and hadn't made any pre-arrangements," said Ron Wade, director of the State Anatomy Board.

The number of unclaimed bodies went from 1,029 in 2012 to 1,504 in fiscal year 2016. So far this year, there have been 1,120. While the Anatomy Board can't say for sure what the cause is, the rise in crime and an opioid epidemic are not being ruled out.

"That's one factor that's brought the numbers to increase in the last couple of years -- the numbers of homicides and drug overdoses," Wade said.

If there's an increase in the number of cases at the medical examiner's office, that affects the anatomy board as well.

"If we have an increase, that effects the medical examiners, and their cases as a matter of circumstances the increase is going to affect us as far as the number of bodies coming in, because it's a very short time period," Wade said.

The bodies stay there a minimum of 14 days. After that, the Anatomy Board director can order a cremation. The ashes are then held for at least a year.

Also on the WBALTV.com:

WEBVTT THE STATE ANATOMY BOARD HOUSEDIN THE UNIVERSITY OF MARYLANDMEDICAL CENTER IS WEHREUNCLAIMED BODIES END UP, ANDACCORDING TO ITS DIRECTOR, SINCEFISCAL YEAR 2012, THE NUMBER OFBODIES THAT END UP HERE HAS BEENGOING UP SIGNIFICANTLY.>> DECEDENTS COME TO US BECAUSEMAYBE THE FAMILIES DO NOT HAVETHE ECONOMIC MEANS TO MAKE ACLAIM AND THE DECEASED DID NOTHAVE INSURANCE AND HAD NOT MADEANY PRE-ARRANGEMENTS.LISA THE NUMBER OF UNCLAIMED: BODIES WENT FROM 1029 IN 2012TO 1504 IN FISCAL YEAR 2016.SO FAR THIS YEAR THERE HAVE BEEN1120.WHILE THE ANATOMY BOARD CAN'TSAY FOR SURE THE CAUSE, A RISEIN CRIME AND AN OPIOD EPIDEMIC-- OPIOID EPIDEMIC ARE NOT BEINGROLLED OUT.>> THAT IS ONE FACTOR THAT HASBROUGHT A SIGNIFICANT INCREASEIN THE LAST COUPLE OF YEARS, THENUMBERS OF HOMICIDE AND DRUGOVERDOSES.>> IF THERE'S AN INCREASE IN THENUMBER OF CASES AT THE MEDICALEXAMINER'S OFFICE, THAT EFFECTSTHE ANATOMY BOARD AS WELL.>> IF WE HAVE AN INCREASE THATAFFECTS THE MEDICAL EXAMINER'SAND THEIR CASES IT IS A MATTEROF CIRCUMSTANCES THAT THEINCREASE WILL AFFECT IS AS FARAS THE NUMBERS OF BODY'S COMINGIN BECAUSE IT IS A VERY SHORTTIME.LISA: THE ANATOMY BOARD KEEPSTHE BODY'S FOR 14 DAYS.AFTER THAT, THE ANATOMY BOARDDIRECTOR CAN CAN ORDER ACREMATION AND THE ASHES ARE HELD

More here:
State Anatomy Board overwhelmed with unclaimed bodies - WBAL Baltimore

The Anatomy Of Courage | HuffPost – Huffington post (press release) (blog)

It takes courage not to be discouraged. That was Benjamin Ferencz, the last surviving Nazi war crimes prosecutor who, at the age of 27, prosecuted two dozen death camp supervisors and who, now age 97, was interviewed on 60 Minutes. He was responding to questions as to how and why his experience had not left him bitter.

But it is also a message for those of us watching a lifetime of effort to move our nation forward, to improve the lives of those left behind, to leave a healthier environment for our children, to control weapons of mass destruction, and many other standards of progress being swept away.

There are many reasons to be discouraged. Energy policy is being turned over to the energy industry. Environmental programs are being dismantled by climate change deniers and anti-science zealots. Public education is being privatized. Affordable health insurance now finances tax cuts for the wealthy. Federal judges are selected for ideological purity.

Most discouraging of all is the commercialization of the presidency. The extended first family blatantly sells White House (or Mar-a-Lago) access to powerful interests around the world. Heads of state are entertained at a private resort, not the White House. The presidents family promotes its hotels, casinos, and beauty products in foreign capitals. Foreign leaders are learning to trade access to their markets in exchange for the U.S. supporting their policy objectives.

It is too bad William Faulkner is not still living. His trilogy The Hamlet, The Town, and The Mansion chronicled the rise of the Snopes family in Southern politics. Corrupt and self-serving to the core. He would now have to add The White House. Looking back, it now seems almost inevitable that corruption on a monumental scale would eventually make it to the top.

A few of us disagree with the pundits who have settled on the last election as a class conflict. Certainly some Trump voters were angry at various elites, liberal and otherwise. But what about the Wall Street elites now running our economy and the corporate elites dismantling worker safety and environmental regulations and helping themselves to public lands. And the conservative dark money elites dismantling anything having Obamas name on it. You will search in vain for any step taken so far or for the next three years that directly and immediately helps low income white people who are, instead, being taken to the cleaners by the Trump elites.

Since few young people today would call themselves idealists, it is left to aging idealists from the 1960s to keep that flickering and archaic torch alive. But Mr. Ferencz is right. It does take courage. Not battlefield courage. But the courage that comes from believing in an American ideal that is far better than what we see today. The courage that believes we are not witnessing a modern day version of the fall of the Roman Empire. The courage that insists when this grim un-American detour is over we will return to our ideal as a nation of principles, political morality, and Constitutional standards.

In the meantime, it takes courage. Courage to persevere. Courage to see farther down the road. Courage to believe a large majority of Americans, including many who voted for this administration and are now experiencing shock at what they got, will return to our traditional beliefs, the faith of our fathers. The courage to know that we will not only endure, we will prevail.

View post:
The Anatomy Of Courage | HuffPost - Huffington post (press release) (blog)

‘Grey’s Anatomy’ Season 13 Episode 23 Promo: Stephanie Takes a Fatal Fall? – Wetpaint

Credit: Richard Cartwright/ABC 2017 Disney | ABC Television Group. All rights reserved.

Greys Anatomy Season 13 has been writing Stephanie Edwards off the show for ten episodes now, but perhaps the end of her storyline will take a violent turn.

A new promo suggests Steph will be going out not with a whimper but with a splat.

Stephanie has become increasingly disillusioned with surgery, and now shes even suspended from the OR, so a career change could be nigh.

But this promo for Season 13 Episode 23 airing this Thursday, May 11 has us worried this doc will actually fall to her death.

In the teaser, we see Stephanie treating her potential murderer, a patient at Grey Sloan Memorial.

Help me, he beseeches her.

Were guessing hes the dangerous patient mentioned by ABCs synopses for both this episode and the May 18 season finale perhaps hes mentally ill.

In the next shot, the man is throwing Stephanie against a wall and pressing a sharp object to her throat.

Next, we see her hurriedly open a door with a keycard. Then, we see her stagger down a flight of stairs in his grasp, followed by a vertiginous shot looking straight down the stairwell.

Above the tense music, we hear a snippet of dialogue. It sounds like shes saying, I cant.

Then comes the scariest shot: The patient is seemingly pushing Stephanie so that shes leaning far out over the stairway railing.

The rest of this promo hypes another major plot twist. At home, Owen answers a knock at the door, and an offscreen male voice asks, Owen Hunt?

Cut to: a shot of Owen sobbing, with Amelia comforting him.

Could we finally be seeing the return of Megan Hunt, Owens sister and Nathans ex? Megan has been missing since their days serving as Army docs together she disappeared on a helicopter trip through unprotected airspace.

If youll recall, Megan discovered Nathan was cheating on her, and Owen encouraged her to board that ill-fated chopper just to get away from Nathan.

Fans have speculated that Megan is due for a reappearance, especially now that Nathan is getting cozy with Meredith. Your new boyfriend finding his ex-girlfriend after years of her being MIA? Thats peak Shondaland, if you ask us.

And we havent even mentioned the first clip of this promo, in which Bailey announces a code orange situation, which often means hazardous materials are at play.

If thehottest Season 13 finale spoilers are any indication, those hazardous materials are of the flammable persuasion

And that would mean Steph and Owen arent the only docs rocked by drama as Season 13 concludes!

Here is the original post:
'Grey's Anatomy' Season 13 Episode 23 Promo: Stephanie Takes a Fatal Fall? - Wetpaint

The anatomy of cardamom – Huffington post (press release) (blog)

Tropical spices have been used in traditional medicine for centuries. Cardamom, the third most expensive spice in the world, is a reservoir of compounds that alleviate a variety of physiological discomforts.

The recent pathetic self-congratulatory tone of the House Republicans with regards to their attempts to fashion a new healthcare act, is hopefully short-lived. In addition to potential procedural hurdles that the bill will likely face in the Senate, Republican senators have already expressed concern over language in parts of the bill. If the Senate passes a bill that is substantially different from the one passed by the House, then the bill would likely have to go back to the House. Historically, about 3% of bills introduced in Congress are enacted into law. The trajectory of the Affordable Care Act can be found at govtrack.us and is shown below [Note: the site is an independent site, and not a government siteit tracks bills and provides statistical analyses of legislation]. From the time of introduction of the bill, September 17, 2009, to it being approved by both the Senate and the House on March 20, 2010, Congress had convened for a total of 90 days.

The current bill, H.R. 1628: American Health Care Act of 2017, will at the very least go through a similar process, which means the earliest we could see it enacted into law could be September 2017. From all indications, if it passes, the new healthcare act will have imposed severe restrictions on access to healthcare for innumerable citizens. In times of scarcity, people typically resort to alternative solutions and its conceivable that scarce access to healthcare will be no different.

In 2015, Marijke Van der Veen, and Jacob Morales from the University of Leicester reported their findings from studying botanical remains recovered during archaeological excavations at Quseir al-Qadim, located on the Red Sea coast of Egypt. Quseir al-Qadim was active as a transport hub during both Roman (ca. AD 1250, when it was known as Myos Hormos), and Islamic periods (ca. AD 10501500, when it was known as Kusayr). The excavations, conducted between 1999 and 2003, revealed at least seven tropical spices including black pepper, ginger, cardamom, turmeric. Based on texts from those periods, it appears these spices were traded for rituals, perfumery, medicinal use, and cooking. Of these, ginger, cardamom and turmeric belong to the family Zingiberaceae the ginger family. [Note: biological classification has many tiers and can be conceptualized as a triangle with its apex at the bottom. The main hierarchy puts species at the apex, with genus before it, and family before genus. This is not unlike zooming out of your house on a mapthe most detailed picture would give the coordinates of your housethis would be the species equivalent; the less detailed picture would give you the city in which your house existsthis would be the genus equivalent; and a still less detailed picture would give the state in which your house existsthis would be the family equivalent. Thus, the scientific name for the ginger root you buy at the grocery store Zingiberaceae Zingiber officinale. Typically, only the genus and species names are used togetherthe family name is not always included.]

The Zingiberaceae family has at least 50 genera (genera is the plural of genus), and more than 1600 species. Turmeric, cardamom, and ginger are three of the 1600 species and their origin has been traced back to India. The Quseir al-Qadim excavations also confirm this based on the trade routes in both the Roman and Islamic periods, and historic texts.

Turmeric, cardamom, and ginger while primarily used as spices in traditional Indian cooking, have also been used in traditional medicine to address different ailments. While there have been recent reports in the popular press about the medicinal properties of turmeric and ginger, much less attention has been given to cardamom. This skewed public interest is illustrated in Google Trends, below.

Elettaria cardamomum, more commonly known as cardamom or green cardamom or true cardamom is distinct from brown/black cardamomAmomum subulatum, although in the early 19th century they were incorrectly considered to be the same genus. The genus name Elettaria comes from the local Indian name for the plant, indigenous to the southwestern part of the Indian peninsula. The 1899 publication of the The United States Dispensatory and Physicians Pharmacology, provides a description of the cardamom plant and states that This valuable plant is a native of the mountains of Malabar, where it springs up spontaneously in the forests after the removal of the undergrowth, and is very extensively cultivated by the natives..The odor of cardamom is fragrant, the taste warm, slightly pungent, and highly aromaticThe seeds should be powdered only when wanted for use, as they retain their aromatic properties best while in the capsule. While India used to be the worlds largest producer of green cardamom, that position now belongs to Guatemala.

The chemical composition, and therefore the flavor, aroma, and biochemical properties of green cardamom and brown/black cardamom are distinct. The limited scientific literature available is more specific to green cardamom, which continues to be the more expensive of the two, and sells for about $35 per pound in the pod. While the shell is also aromatic, the seeds are the primary source of the aromatic componentsvolatile oils and other phytochemicalsby some estimates up to 150 unique components. Because of centuries of anecdotal evidence on the medicinal properties of green cardamom in humans, there have now been a few reports on studies in laboratory animals in order to determine the active principles conferring the medicinal properties. Perhaps the most convincing ones are related to the analgesic and antispasmodic effects of oil extracted from the seeds. In fact, a closer look at the chemical composition of cardamom oil suggests that one of the primary components of the oil has the ability to relax smooth muscles, effectively reducing, if even modestly, some types of gastric discomfort. It is perhaps for this reason that crushed cardamom is an essential component of masala chai (masala=spice; chai=tea), spiced tea now sold well beyond Indian shores, and for a hefty price!

The NIH, whose funding is also on 45s chopping block, had initiated a program on complementary medicine in 2005, because it recognized that People have used complementary and alternative medicine (CAM) practices for thousands of years in pursuit of health and well-being. But with looming budget cuts for the NIH, it is unclear how these programs will will be affected. Citizens will thus be doubly robbed of healthonce through a lopsided healthcare law, and again by reducing funding to healthcare research. One wonders how trading in commodities will be affected as a consequence particularly as it relates to members of the Zingiberaceae!

See the rest here:
The anatomy of cardamom - Huffington post (press release) (blog)

Cannabis Reverses Brain Aging – Anti Aging News

Most people know the average person's memory dissipates during the aging process. University of Bonn scientists teamed up with academicians at The Hebrew University of Jerusalem to determine the impact of cannabis on the brain's aging process. These researchers determined cannabis reverses aging processes within the brains of mice.

The Findings

The study revealed that older mice reverted back to the state of 2-month old mice after enjoying an extended low-dose cannabis treatment. These findings are important as they show there are additional options for the treatment of dementia in humans. The study results were recently publicized in the Nature Medicine journal.

The Impact of the Aging Process on the Brain

The brain ages just like every other organ in the human body. The result of this aging process is a decrease in cognitive ability. As an example, people tend to find it difficult to pay attention to multiple things at the same time or learn new concepts/skills as they age. Though this is a normal process, it also leads to dementia. Researchers have been searching for ways to mitigate or completely reverse this process. The scientists referenced above have reversed the processin mice with cannabis treatment. Mice have short life spans and show significant cognitive deficits after a year of life.

About the Study

The researchers provided mice with a small amount of THC. The low dose of cannabis treatment was selected so the mice did not experience a euphoric effect. THC is the active ingredient in cannabis. The treatment was provided to mice that were two months old, a year old and 18 months old. The treatment was applied across four weeks. The scientists then tested the animals' memory performance and learning capacity.

Mice provided with the placebo had the expected age-related memory and learning losses. Mice provided with cannabis enjoyed cognitive functions equal to those of of two-month-old mice. The cannabis treatment totally reversed performance loss in mice. The scientists studiedthe gene activity and brain tissue of treated mice to determine exactly what sort of effect cannabis treatment had in particularly old mice.

Following treatment, the molecular signature did not match that of old mice. Instead, it was similar to young mice. Furthermore, the quantity of links in the brain's nerve cells increased. These cells are vital to one's ability to learn. The bottom line is that cannabis treatment turned back the molecular clock in mice and it might be able to do the same in humans.

What led up to the Research

The cannabis treatment success stems from years of intense research. The scientists found the brain ages more rapidly when mice are not equipped with functional THC receptors. Cannabinoid 1 receptors are best defined as proteins where substances halt and stimulate a signal chain. These receptors are the cause of the euphoric effects of THC in marijuana and hashish. THC replicates the effects of the cannabinoids that are naturally created in the body. Cannabinoids perform vital functions within the brain. As one ages, the number of cannabinoids produced in the brain decrease. As the cannabinoid system declines the brain ages quite rapidly.

The Next Step

The next logical step is for researchers to perform clinical trials to determine if cannabis also reverses the aging process in the brains of human beings. Cannabis is widely usedfor medical purposes.It is also possible that cannabis boosts cognitive ability in aging adults. Though mice are not exactly the same as humans, the research team believes cannabis treatment will prove to be an effective means of treating dementia suffered by human beings across the world.

View original post here:
Cannabis Reverses Brain Aging - Anti Aging News

Scientists develop novel chemical ‘dye’ to improve liver cancer imaging – Science Daily


Science Daily
Scientists develop novel chemical 'dye' to improve liver cancer imaging
Science Daily
We are hopeful that this advancement in nanomedicine will lead to safer and more accurate diagnosis of liver cancer. Moving forward, we plan to conduct further pre-clinical safety studies for our contrast agents, with the end goal being clinical ...

and more »

Go here to read the rest:
Scientists develop novel chemical 'dye' to improve liver cancer imaging - Science Daily

Richard Rodriguez, Celebrity Fitness Trainer, Discusses the Benefits of Somatropin HGH Therapy – Digital Journal

What Can Growth Hormone Therapy Do for You? Richard Rodriguez, Celebrity Fitness Trainer, Discusses the Benefits of Somatropin HGH Therapy.

Miami, FL 33132 - May 8, 2017 - (Newswire.com)

Richard Rodriguez is an iconic and legendary figure within the fitness community. His companies span all across the globe and have dominated the peptides, transdermal, hormone and contest prep market. He possesses over 25years experience in diet plans, contest prep and personal training. Also an expert in transdermal, peptides and hormone optimization. This is the site for all your transdermal, peptides and contest prep needs.

The growth hormone (GH) is responsible for slowing the aging process, which can aid exponentially in a bodybuilding regimen. As people get older, the growth hormone naturally starts to decline in their bodies. After 30, the hormone declines about 25 percent every ten years. This means that when youre 60, you have 25 percent of the original levels.

The pituitary gland naturally produces the growth hormone, and it stimulates cell reproduction and growth in the body. It also helps to regulate body fluids, body composition, sugar and fat metabolism and muscle and bone growth, and it may also help with heart function. Growth hormone therapy can slow down the aging process, and this synthetic hormone was first developed in 1985 and is approved by the FDA.

Somatropin is the isolated form of human growth hormone (HGH). The hormone was first discovered in the 1920sand was isolated in 1956, when research on its function in humans began. Regardless of its form, we still typically refer to somatropin as human growth hormone, growth hormone, GH, HGH... it's all the same. Somatropin HGH was originally harvested from the pituitary glands of cadavers. This process continued up until the 1980s, when the practice was banned due to numerous cases of CreutzfeldtJakob disease (mad cow disease) and central nervous system lymphomas that were reported with its use and traced back to contaminated batches of somatropin harvested from human cadavers with those diseases. Subsequently, bio-tech giant Genentech, and drug company Eli Lilly, employed recombinant DNA technology to fabricate a bio synthetic version of growth hormone that was FDA approved in 1987. Their products were an exact DNA match to the 191 amino acids chain somatropin produced by the human body.

Over the years, the benefits of somatropin were well reported and quite varied. To this day, new research regularly comes to light that demonstrates new benefits and uses for somatropin.For thosereading this, the majority interest lies in somatropin's positive effect on:

In the body, somatropin, the natural form ofhuman growth hormone, is produced when the hypothalamus stimulates the anterior pituitary gland just like luteinizing hormone stimulates the testes to produce testosterone. The effects of somatropin on the human body are as varied as they are desirable. Somatropin promotes and enhances protein synthesis in muscle tissue to effect growth, recovery and repair. Somatropin is directly involved in building new muscle. Research also demonstrates somatropin is involved in metabolizing body fat (lipolysis) and the oxidation process which turns fat into energy. Somatropin also improves sleep patterns, making for deeper, more restful sleep and more time in the REM sate of sleep where growth, recovery and tissue repair are the most efficient. Accordingly, employing somatropin is one of the standard means by which pro bodybuilders have increased and maintained muscle mass while dieting for years.

Clearly, somatropin represents numerous benefits to the athlete. Research demonstrates that somatropin may even be superior to testosterone and its steroid derivatives, because it has a paucity of side effects in limited doses, does not aromatize or convert to estrogen and it's not androgenic and thus causes no androgenic side effects. In combination with testosterone, athletes have the absolute best of both worlds.

Since somatropin is a critical hormone for the health and well-being of all humans, not just athletes, the dosing of somatropin growth hormone must be fairly precise for the optimal functioning of the various physiological processes of growth and repair of body tissues including muscle and the metabolization of body fat. Not only is the dosing of somatotropin important, so is the time of day you take it. As with all things we employ to enhance performance, or quality of life, we continually strive for what is generally accepted as optimal. In the case of Somatropin, optimal is a fairly simple application.

Somatropin Dosing

As with most cases of off-label uses of compounds, it is the athletes looking to increase performance who end up being the de facto lab rats in the case, because the medical community at large tends to ignore non-medical uses of any compound, somatropin included. The bodybuilding community has taught us, over years and years of trail and error, that the maximum dose of somatropin should never exceed 8 IU (International Units) a day. That's not to say that some extreme practitioners haven't gone as high as 24 IU a day. The resulting bloat because of the water retention caused by such an extreme dose was about the only noticeable difference between such a high dose and what the athletic community would deem normal 4 to 8 IU a day. If nothing else, this goes to prove the rather innocuous nature of somatropin. You really can't overdose on it and experience any significant health risk not short-term, anyway. A long-term study on such unreasonable dosing would be as unethical, as it would be cost-prohibitive.However, suffice to say, based on what we do know today, somatropin, at any dose is a relatively safe drug. That's not say that there is such a thing as a safe drug, but as far as the multitudes of substances we routinely put into our bodies even items purchased over-the-counter comparatively speaking, somatropin is perhaps the least problematic of them all.

So what is the optimal dose of somatropin one should take to realize its maximum benefits, with the least water retention? Again, this was determined by trial and error among the athletic community. While the published studies on growth hormone rarely exceed 2 IU per day, athletes have been performing increasingly well on 4 to 8 IU per day, as depicted above. However, through the quasi-scientific, empirical, process of trial and error among athletes, we've learned that in order to reap the full benefit of somatropin, the timing and consistency is more important than the total amount taken. For example, through the cause and effect monitoring of athletes using somatropin, we know today that consuming a 100 IU box of somatropin over 20 days at 4 IU a day is more beneficial than taking the same 100 IU over a period of 10 days, at 8 IU a day. Additionally, we now know that somatropin taken in conjunction with testosterone is the most effective manner of use.

We know this because research in animals has demonstrated that somatropin, like testosterone, seems to divert the calories from food away from fat synthesis and toward protein synthesis, to the degree that somatropin is noted to be as powerful as testosterone in stimulating protein synthesis and nitrogen retention in muscle. We see this as proof in humans, based on the observation that those who are clinically GH and testosterone deficient, have reduced lean body mass and increased fat mass, particularly central abdominal fat. Conversely, the opposite is true. This gives us an empirical perspective as demonstrating that the higher the level of somatropin, concomitant with testosterone, the body synthesizes more muscle mass and less fat than with either compound alone. Male test subjects taking between 250 and 500 mg of testosterone a week, in conjunction with 4 to 8 IU of somatropin daily, noted extremely satisfactory increases in lean mass while shedding body fat, especially in the abdominal area.

Best Time To Administer Somatropin

Within 15 to 20 minutes after a subcutaneous (sub-Q) injection,somatropin blood concentrations immediately fall off. This is because the body does not use somatropin growth hormone in its original state. It must be converted in the liver to somatomedin-C, or IGF-1. IGF-1 is a 70-amino acid chain hormone that has been shown to be the most potent growth factor derived by GH release or administration. It is the hormone that turns on the processes of tissue growth and repair, especially in muscle. IGF-1 production is regulated by factors other than somatotropin growth hormone, most notably nutritional and thyroid function; however, when growth hormone is released by the body, or injected as somatropin, and it goes to the liver to stimulate a set of growth factors, IGF-1 has demonstrated to be the most potent and well-established of all.

The timing aspect of all of this revolves around insulin. This hormone works completely against somatropin HGH. While insulin can be highly anabolic, insulin, in the presence of somatropin growth hormone, renders both ineffective. They essentially cancel each other out. Regulating these hormones is a kind of natural balancing act the body goes through. Lower insulin levels can cause the body to produce more pituitary growth hormone. Therefore, somatropin is the most effective when insulin levels in the body are at their lowest.

Using blood sugar as an indicator, what is the best time to take somatropin?

There are actually two times of day when insulin is at its lowest, providing two effectively optimal windows of use. Immediately upon waking in the morning, insulin is at its lowest level. That gives us the first optimal window of use. It's important to take advantage of this window prior to eating, as any food ingested will immediately incite an insulin response. Bodybuilders and elite athletes also know that the next time insulin will be at a very low level is immediately following a strenuous workout session. This gives us two optimal windows of use, either immediately upon waking (before eating) or immediately post-training. It is not uncommon for many elite athletes to take advantage of both windows and administer somatropin twice daily once immediately upon waking and the other immediately post-training.

Before You Decide To Use Somatropin, Consult Your Doctor

You should not use somatropin if you are either allergic to it, or if you currently suffer from complications from recent surgery, or other serious complications such as:

Such conditions can become worsened with somatropin. It is important to seek medical counsel before embarking on any therapy which includes somatropin or other hormones affecting tissue growth.

Somatropin Side effects

In clinical studies with somatropin growth hormone, some individuals experienced:

Any patient who has a growth hormone deficiency and does not respond to therapy with somatropin should be tested for thyroid problems or antibodies to human growth hormone. Either of these conditions can reduce the effectiveness of somatropin human growth hormone.

The availabilityis quicklyfilling up with athletes he will be working with, so if you are interested now, schedule yourFree 30 Minute ConsultationNow or Fill out anapplicationfor consideration.

Related Links Free 30 Minute Consultation Peptide Blog

Related Files growth hormone therapy - What Can Growth Hormone Therapy Do for Me.pdf WFNN - Somatropin.pdf

Related Images

Press Release Service by Newswire.com

Original Source: Richard Rodriguez, Celebrity Fitness Trainer, Discusses the Benefits of Somatropin HGH Therapy

See more here:
Richard Rodriguez, Celebrity Fitness Trainer, Discusses the Benefits of Somatropin HGH Therapy - Digital Journal